Welcome to our dedicated page for Kenvue SEC filings (Ticker: KVUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Kenvue Inc. (NYSE: KVUE) SEC filings, giving investors a primary source for the company’s regulatory disclosures. As the world’s largest pure-play consumer health company by revenue, Kenvue uses its SEC reports to detail financial performance, risk factors, governance matters and significant corporate events related to its portfolio of brands such as Aveeno®, BAND-AID® Brand, Johnson’s®, Listerine®, Neutrogena®, Tylenol® and Zyrtec®.
Among the most important documents for KVUE are current reports on Form 8-K. In 2025, Kenvue filed several 8-Ks to furnish quarterly earnings press releases and to describe leadership changes, preliminary financial results and the Board’s comprehensive review of strategic alternatives. A key 8-K filed on November 3, 2025 outlines an Agreement and Plan of Merger with Kimberly-Clark Corporation, under which a Kimberly-Clark subsidiary will merge with and into Kenvue and Kenvue will ultimately become part of a wholly owned Kimberly-Clark subsidiary. That filing explains the merger structure, the cash and stock consideration for each share of Kenvue common stock, conditions to closing, and termination and fee provisions.
Investors can also use Kenvue’s filings to understand how management presents non-GAAP financial measures. The company’s 8-K earnings materials define metrics such as Adjusted gross profit margin, Adjusted operating income and margin, Adjusted net income, Adjusted diluted earnings per share, Adjusted EBITDA margin, Adjusted effective tax rate, Free cash flow and Organic sales, and reconcile them to the most comparable U.S. GAAP measures. These disclosures clarify how Kenvue evaluates operating efficiency, profitability and cash generation over time.
On this page, Stock Titan surfaces Kenvue’s SEC submissions as they are made available on EDGAR and pairs them with AI-powered summaries to explain the key points in plain language. Users can quickly scan new 10-K and 10-Q reports when filed, review 8-Ks for material events such as the Kimberly-Clark merger agreement or leadership transitions, and examine any proxy materials related to shareholder votes. This combination of real-time filings access and AI explanations helps investors follow how regulatory disclosures may affect KVUE shareholders and the future of the Kenvue business within the consumer health sector.
Kenvue Inc. director Jeffrey C. Smith reported purchases of the company’s common stock through accounts managed by Starboard Value LP. On 12/11/2025, the Starboard Accounts bought 3,177,694 shares at a weighted-average price of $17.4318 per share, and on 12/12/2025 they bought 3,200,000 shares at a weighted-average price of $17.373 per share. Following these transactions, 27,307,632 Kenvue shares were beneficially owned by the Starboard Accounts and reported as indirectly owned by Smith. The filing notes that, as a managing member of Starboard, he may be deemed to beneficially own these securities for Section 16 purposes but disclaims beneficial ownership except to the extent of his pecuniary interest. Smith also holds 13,641.878 deferred share units, each representing one share of common stock to be delivered after his separation from service, including units credited as dividend equivalents.
Kenvue Inc. director Jeffrey C. Smith reported his latest beneficial ownership in the company’s stock. The filing shows indirect ownership of 20,929,938 shares of Kenvue common stock through Starboard Value LP-managed accounts. Smith also acquired 1,451 Deferred Share Units (DSUs) on 12/01/2025, which are a form of stock-denominated director compensation.
Each DSU represents the right to receive one share of Kenvue common stock, to be settled after Smith’s separation from service under the company’s deferred fee plan for directors. Following this grant, he directly holds 13,641.878 DSUs, while his indirect holdings through Starboard reflect his economic interest in accounts managed by that firm.
Kenvue Inc. director reports additional deferred share units
A director of Kenvue Inc. (KVUE) filed a Form 4 reporting the acquisition of 1,451 Deferred Share Units ("DSUs") on 12/01/2025 under the company's Amended and Restated Deferred Fee Plan for Directors. Each DSU represents the right to receive one share of Kenvue common stock, to be settled in shares after the director separates from service. Following this transaction, the director beneficially owns a total of 13,641.878 DSUs, which includes DSUs acquired as dividend equivalents.
Kenvue Inc.'s General Counsel reported equity transactions involving company stock on Form 4. On 12/01/2025, 4,378.21 restricted stock units were converted into the same number of common shares at an exercise price of $0, reflecting the vesting of previously granted equity awards. On the same date, 2,031 shares of common stock were withheld at a price of $17.22 per share to cover taxes due at vesting. After these transactions, the reporting person directly owned 28,839.324 shares of Kenvue common stock, including shares acquired through dividend reinvestment. The underlying award vests in three equal installments on 12/01/2024, 12/01/2025, and 12/01/2026, contingent on continued service.
Kenvue Inc. executive reports RSU vesting and share ownership update. A Group President for EMEA & LA exercised 1,779 restricted stock units into common stock on 12/01/2025 at an exercise price of $0, retaining all shares and paying related tax withholdings in cash. Following this transaction, the insider beneficially owns 58,095.03 shares of Kenvue common stock in direct form.
The Form 4 also shows 1,778.07 restricted stock units remaining beneficially owned after the reported transaction. The underlying RSU award is scheduled to vest in three equal installments on 12/01/2024, 12/01/2025, and 12/01/2026, conditioned on continued service. The filing notes that each unit corresponds on a 1‑for‑1 basis with Kenvue common stock and that the reported share balance includes amounts acquired through dividend reinvestment.
Kenvue Inc. Chief Operations Officer reported routine equity compensation activity. On 12/01/2025, the officer converted 2,775.95 restricted stock units into the same number of common shares at an exercise price of $0, reflecting vesting of prior awards. On the same date, 1,180 common shares were withheld at a price of $17.22 to cover taxes due upon RSU vesting. After these transactions, the officer directly owned 66,037.18 shares of Kenvue common stock and held 3,009.28 RSUs, which include units acquired through dividend reinvestment and an award that vests in three equal installments through 12/01/2026.
Kenvue Inc. director reported a routine insider transaction involving deferred equity compensation. On 12/01/2025, the director acquired 1,451 Deferred Share Units (DSUs)35,906.289 DSUs, a figure that includes amounts accumulated through dividend reinvestment.
Kenvue Inc. reported an insider equity transaction by its Chief People Officer. On 12/01/2025, the officer exercised 2,020.78 restricted stock units that convert 1-for-1 into common stock at an exercise price of $0, increasing directly held common shares to 33,380.14 before related tax withholding.
On the same date, 731 shares of common stock were withheld at a price of $17.22 to cover taxes due upon vesting of these restricted stock units, leaving 32,649.14 common shares held directly. After these transactions, the officer also held 2,222.28 restricted stock units, including units acquired through dividend reinvestment, which may vest in future installments subject to continued service.
Kenvue Inc. insider updates holdings after equity award vesting. The company’s Chief Scientific Officer reported the vesting and settlement of 1,538.75 Restricted Stock Units into an equal number of Kenvue common shares on 12/01/2025 at an exercise price of $0, reflecting equity compensation rather than an open‑market purchase.
To cover taxes due at vesting, 788 common shares were withheld and disposed of at a price of $17.22 per share. Following these transactions, the officer directly holds 44,879.51 shares of Kenvue common stock and 1,538.86 RSUs, which include units acquired through dividend reinvestment and are scheduled to vest in installments subject to continued service through the vesting dates.
Kenvue Inc. (KVUE) reported insider equity activity by its Chief People Officer on 11/18/2025. Restricted stock units converted into common shares on a one-for-one basis, including 309 and 123 units that became common stock. A matching 309 and 123 shares were withheld to cover FICA taxes arising from the officer being retirement eligible.
After these transactions, the officer directly beneficially owned 31,359.36 shares of Kenvue common stock. The filing also notes remaining restricted stock unit awards of 8,384.47 and 12,622.07 units, which vest in three equal installments on 03/05/2025, 03/05/2026, 03/05/2027 and on 03/10/2026, 03/10/2027, 03/10/2028, respectively, subject to continued service.
FAQ
What is the current stock price of Kenvue (KVUE)?
What is the market cap of Kenvue (KVUE)?
